Long COVID Recovery: Why Standard Treatments Often Fail and What Actually Works

What is Long COVID?

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), is defined by the World Health Organization and CDC as symptoms that persist for more than 4 weeks after the initial infection, and cannot be explained by another diagnosis.

It can affect anyone — regardless of age, severity of the original infection, or vaccination status. Research suggests that 10–30% of people who had COVID-19 go on to develop Long COVID.

Common Symptoms

Long COVID is highly variable, but the most frequently reported symptoms include:

- Extreme fatigue (often worsening after activity — post-exertional malaise)

- Brain fog and cognitive difficulties

- Shortness of breath and chest pain

- Heart palpitations or POTS (Postural Orthostatic Tachycardia Syndrome)

- Sleep disturbances

- Joint and muscle pain

- Loss of taste/smell

- Anxiety, depression, and neurological symptoms

Many patients describe it as feeling like their body is “stuck” in a state of chronic inflammation and dysfunction.

Current Standard Medical Protocol

Most conventional treatment approaches focus on symptom management rather than addressing root causes. These typically include:

- Graded Exercise Therapy (GET)

- Cognitive Behavioral Therapy (CBT)

- Medications for specific symptoms (beta-blockers, antidepressants, sleep aids)

- Pulmonary rehabilitation

- Rest and pacing

While these approaches help some patients, large-scale studies show they often provide only limited or temporary relief for many others.

Why Standard Treatments Often Fail

Several high-quality studies reveal why conventional care frequently falls short:

- Persistent Viral Reservoirs: Research published in Nature and The Lancet has found remnants of SARS-CoV-2 virus in tissues (including the gut, brain, and heart) long after the acute infection clears. Standard treatments do not address this ongoing viral presence.

- Autoimmunity: Multiple studies (including one in Nature 2023) have shown that many Long COVID patients develop autoantibodies that attack their own tissues — similar to autoimmune diseases. Symptom management alone does not correct this immune dysregulation.

- Microvascular and Mitochondrial Damage: COVID-19 can damage small blood vessels and impair cellular energy production (mitochondria). A 2022 study in JAMA found significant mitochondrial dysfunction in Long COVID patients, which graded exercise can sometimes worsen.

- Limited Efficacy of GET and CBT: A large 2023 review in BMJ and patient surveys from organizations like the ME Association found that many patients experience worsening symptoms with graded exercise, leading to criticism of these as first-line treatments.

In short, most standard protocols treat symptoms in isolation while the underlying drivers — persistent inflammation, autoimmunity, and toxin/viral burden — remain unaddressed.

What Actually Works: Emerging Approaches

More effective strategies focus on root-cause resolution:

- Addressing persistent inflammation and immune dysregulation

- Supporting mitochondrial function and vascular health

- Reducing the overall toxic and inflammatory burden in the body

One of the most promising areas involves advanced blood purification therapies that can remove inflammatory mediators, autoantibodies, and other harmful substances from circulation.

Why INUSpheresis® May Be a Strong Option

INUSpheresis® is a specialized form of therapeutic apheresis that uses advanced double-filtration technology to selectively remove toxins, inflammatory proteins, autoantibodies, and other disease-promoting substances from the blood plasma.

Several studies and clinical observations (particularly from European centers) have shown positive results in Long COVID patients, including:

- Reduction in inflammatory markers

- Improvement in fatigue and brain fog

- Better overall energy and quality of life

Unlike standard treatments that manage symptoms, INUSpheresis works at the blood level to reduce the circulating burden of harmful substances that may be driving ongoing symptoms. For many patients who have not responded to conventional care, it offers a more targeted and mechanistic approach to recovery.

At ZIV, we specialize in helping patients access this advanced therapy through our vetted partner clinics in Europe and the UAE.

Bottom Line:

Long COVID is complex, and one-size-fits-all treatments often fail because they don’t address the multiple underlying mechanisms at play. For those who have tried standard approaches without success, advanced options like INUSpheresis® represent a promising path forward — one that targets the problem at its source rather than just managing the symptoms.

If you or someone you know is still struggling with Long COVID, feel free to reach out. We’re here to help you explore real solutions.